|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/18/20 Navidea Biopharmaceuticals, Inc. 10-K 12/31/19 97:10M RDG Filings/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.18M
2: EX-4.3 Instrument Defining the Rights of Security Holders HTML 42K
3: EX-10.27 Material Contract HTML 92K
4: EX-10.28 Material Contract HTML 102K
5: EX-21.1 Subsidiaries List HTML 26K
6: EX-23.1 Consent of Experts or Counsel HTML 30K
7: EX-24.1 Power of Attorney HTML 33K
8: EX-31.1 Certification -- §302 - SOA'02 HTML 32K
9: EX-32.1 Certification -- §906 - SOA'02 HTML 28K
95: R1 Document And Entity Information HTML 67K
42: R2 Consolidated Balance Sheets HTML 133K
31: R3 Consolidated Balance Sheets (Parentheticals) HTML 48K
64: R4 Consolidated Statements of Operations HTML 109K
94: R5 Consolidated Statements of Comprehensive Loss HTML 38K
41: R6 Consolidated Statements of Stockholders' (Deficit) HTML 125K
Equity
30: R7 Consolidated Statements of Stockholders' (Deficit) HTML 30K
Equity (Parentheticals)
62: R8 Consolidated Statements of Cash Flows HTML 112K
97: R9 Note 1 - Organization and Summary of Significant HTML 127K
Accounting Policies
55: R10 Note 2 - Liquidity HTML 43K
24: R11 Note 3 - Discontinued Operations HTML 33K
72: R12 Note 4 - Revenue From Contracts With Customers HTML 100K
82: R13 Note 5 - Fair Value HTML 54K
54: R14 Note 6 - Stock-based Compensation HTML 70K
23: R15 Note 7 - Loss Per Share HTML 33K
71: R16 Note 8 - Accounts and Other Receivables and HTML 41K
Concentrations of Credit Risk
81: R17 Note 9 - Property and Equipment HTML 48K
53: R18 Note 10 - Investment in Macrophage Therapeutics, HTML 57K
Inc.
25: R19 Note 11 - Accounts Payable, Accrued Liabilities HTML 40K
and Other
57: R20 Note 12 - Notes Payable HTML 53K
89: R21 Note 13 - Leases HTML 69K
38: R22 Note 14 - Commitments and Contingencies HTML 73K
27: R23 Note 15 - Equity Instruments HTML 66K
56: R24 Note 16 - Income Taxes HTML 130K
88: R25 Note 17 - Segments HTML 144K
37: R26 Note 18 - Agreements HTML 43K
26: R27 Note 19 - Employee Benefit Plan HTML 32K
58: R28 Note 20 - Supplemental Disclosure for Statements HTML 34K
of Cash Flows
87: R29 Note 21 - Subsequent Events HTML 34K
84: R30 Significant Accounting Policies (Policies) HTML 177K
74: R31 Note 1 - Organization and Summary of Significant HTML 44K
Accounting Policies (Tables)
21: R32 Note 4 - Revenue From Contracts With Customers HTML 75K
(Tables)
51: R33 Note 5 - Fair Value (Tables) HTML 46K
85: R34 Note 6 - Stock-based Compensation (Tables) HTML 64K
75: R35 Note 8 - Accounts and Other Receivables and HTML 38K
Concentrations of Credit Risk (Tables)
22: R36 Note 9 - Property and Equipment (Tables) HTML 46K
52: R37 Note 11 - Accounts Payable, Accrued Liabilities HTML 36K
and Other (Tables)
86: R38 Note 13 - Leases (Tables) HTML 63K
73: R39 Note 15 - Equity Instruments (Tables) HTML 44K
90: R40 Note 16 - Income Taxes (Tables) HTML 117K
60: R41 Note 17 - Segments (Tables) HTML 137K
34: R42 Note 1 - Organization and Summary of Significant HTML 111K
Accounting Policies (Details Textual)
44: R43 Note 1 - Organization and Summary of Significant HTML 53K
Accounting Policies - Assumptions Used to
Calculate Fair Value of Stock Option Awards
Granted (Details)
91: R44 Note 2 - Liquidity (Details Textual) HTML 80K
61: R45 Note 3 - Discontinued Operations (Details Textual) HTML 37K
36: R46 Note 4 - Revenue From Contracts With Customers HTML 66K
(Details Textual)
45: R47 Note 4 - Revenue From Contracts With Customers - HTML 38K
Change in Deferred Revenue and Accumulated Deficit
(Details)
92: R48 Note 4 - Revenue From Contracts With Customers - HTML 43K
Disaggregation of Revenue (Details)
59: R49 Note 4 - Revenue From Contracts With Customers - HTML 37K
Changes in Contract Liabilities (Details)
67: R50 Note 5 - Fair Value (Details Textual) HTML 31K
78: R51 Note 5 - Fair Value - Financial Liabilities HTML 43K
Measured at Fair Value on a Recurring Basis
(Details)
50: R52 Note 6 - Stock-based Compensation (Details HTML 67K
Textual)
20: R53 Note 6 - Stock-based Compensation - Summary of HTML 60K
Stock Option Activity (Details)
66: R54 Note 6 - Stock-based Compensation - Summary of HTML 44K
Unvested Restricted Stock (Details)
77: R55 Note 7 - Loss Per Share (Details Textual) HTML 32K
49: R56 Note 8 - Accounts and Other Receivables and HTML 38K
Concentrations of Credit Risk (Details Textual)
19: R57 Note 8 - Accounts and Other Receivables and HTML 35K
Concentrations of Credit Risk - Accounts and Other
Receivables (Details)
68: R58 Note 9 - Property and Equipment (Details Textual) HTML 28K
76: R59 Note 9 - Property and Equipment - Summary of Major HTML 48K
Classes of Property and Equipment (Details)
43: R60 Note 10 - Investment in Macrophage Therapeutics, HTML 105K
Inc. (Details Textual)
32: R61 Note 11 - Accounts Payable, Accrued Liabilities HTML 34K
and Other (Details Textual)
65: R62 Note 11 - Accounts Payable, Accrued Liabilities HTML 35K
and Other - Accrued Liabilities and Other
(Details)
96: R63 Note 12 - Notes Payable (Details Textual) HTML 147K
40: R64 Note 13 - Leases (Details Textual) HTML 61K
29: R65 Note 13 - Leases - Impact of the Adoption of ASU HTML 42K
2016-02 on Our Balance Sheet (Details)
63: R66 Note 13 - Leases - Amount, Timing and Uncertainty HTML 57K
of Cash Flows Arising From Operating Leases
(Details)
93: R67 Note 14 - Commitments and Contingencies (Details HTML 102K
Textual)
39: R68 Note 15 - Equity Instruments (Details Textual) HTML 165K
33: R69 Note 15 - Equity Instruments - Outstanding HTML 45K
Warrants (Details)
17: R70 Note 16 - Income Taxes (Details Textual) HTML 59K
46: R71 Note 16 - Income Taxes - Components of Deferred HTML 52K
Tax Assets (Details)
79: R72 Note 16 - Income Taxes - Net Operating Loss and HTML 102K
Credit Carryforwards (Details)
69: R73 Note 16 - Income Taxes - Reconciliations Between HTML 56K
the Statutory Federal Income Tax Rate and the
Effective Tax Rate (Details)
18: R74 Note 17 - Segments (Details Textual) HTML 38K
47: R75 Note 17 - Segments - Segment Information (Details) HTML 117K
80: R76 Note 18 - Agreements (Details Textual) HTML 71K
70: R77 Note 19 - Employee Benefit Plan (Details Textual) HTML 28K
16: R78 Note 20 - Supplemental Disclosure for Statements HTML 66K
of Cash Flows (Details Textual)
48: R79 Note 21 - Subsequent Events (Details Textual) HTML 46K
35: XML IDEA XML File -- Filing Summary XML 178K
83: EXCEL IDEA Workbook of Financial Reports XLSX 93K
10: EX-101.INS XBRL Instance -- navb-20191231 XML 2.75M
12: EX-101.CAL XBRL Calculations -- navb-20191231_cal XML 141K
13: EX-101.DEF XBRL Definitions -- navb-20191231_def XML 2.14M
14: EX-101.LAB XBRL Labels -- navb-20191231_lab XML 1.49M
15: EX-101.PRE XBRL Presentations -- navb-20191231_pre XML 2.10M
11: EX-101.SCH XBRL Schema -- navb-20191231 XSD 274K
28: ZIP XBRL Zipped Folder -- 0001437749-20-005567-xbrl Zip 259K
Exhibit 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Jed A. Latkin, certify that:
1. I have reviewed this annual report on Form 10-K of Navidea Biopharmaceuticals, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
/s/ Jed A. Latkin |
|
|
|
|
|
|
Chief Executive Officer, Chief Operating Officer, and Chief Financial Officer |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/18/20 | |||
| For Period end: | 12/31/19 | S-3 | ||
| List all Filings | ||||